Letermovir for prevention of cytomegalovirus reactivation in haploidentical and mismatched adult donor allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide for graft-versus-host disease prophylaxis

Cytomegalovirus (CMV) is a common viral infection in recipients of allogeneic hematopoietic cell transplantation (allo HCT).1,2 Untreated CMV infection results in significant morbidity and mortality in this population, necessitating the use of pre-emptive anti-viral therapies in patients with detectable viremia.3,4 CMV-active antiviral agents have significant adverse effects including myelosuppression (ganciclovir and valganciclovir), or renal injury (foscarnet), among others, leading to additive toxicities in allo HCT recipients requiring treatment for CMV.

Source: Biology of Blood and Marrow Transplantation - October 10, 2020 Category: Hematology Authors: A. Lin, J. Flynn, L. DeRespiris, B. Figgins, M. Griffin, C. Lau, A. Proli, S.M. Devlin, C. Cho, R. Tamari, A.A. Jakubowski, E.B. Papadopoulos, S.A. Giralt, M.A. Perales, S.K. Seo, B. Shaffer Source Type: research